<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846181</url>
  </required_header>
  <id_info>
    <org_study_id>MO002A</org_study_id>
    <nct_id>NCT02846181</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanwa Kagaku Kenkyusho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanwa Kagaku Kenkyusho Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The primary objectives of the study are:

        -  To assess the mass balance recovery after a single PO dose of [14C]-SK-1405

        -  To provide plasma, urine and faecal samples for metabolite profiling and structural
           identification
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>14C radioactivity concentration excreted in urine</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>14C radioactivity concentration excreted in faeces</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>14C radioactivity concentration in whole blood</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>14C radioactivity concentration in plasma</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-SK-1405</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Age 30 to 65 years of age

          -  Body mass index of 18.0 to 30.0 kg/m2

          -  Must be willing and able to communicate and participate in the whole study

          -  Must provide written informed consent

          -  Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools
             per day)

          -  Must agree to use an adequate method of contraception

        Exclusion Criteria:

          -  Participation in a clinical research study within the 3 months prior to IMP dose

          -  Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          -  Subjects who have previously been enrolled in this study

          -  Subjects who have been dosed with SK-1405 in the past

          -  Subjects who are taking, or have taken, antiepileptic and/or antidepressant medication
             in the 6 months prior to dosing

          -  Subjects who are taking, or have taken, any prescribed medication in the 28 days prior
             to dosing, unless judged as not clinically significant by the investigator and sponsor

          -  Subjects who are taking, or have taken, any over-the-counter medication (with the
             exception of up to 2,000 mg/day paracetamol/acetaminophen) in the 7 days prior to
             dosing, unless judged as not clinically significant by the investigator and sponsor

          -  Use, during the 28 days prior to dosing, of any medicine or herbal remedy (such as St
             John's wort) known to induce or inhibit CYP enzymes, unless judged as not clinically
             significant by the investigator and sponsor

          -  History of any drug or alcohol abuse in the past 2 years

          -  History of clinically significant neurological conditions

          -  A QTcF &gt;450 msec at screening, admission or pre-dose (as confirmed by a repeat ECG)

          -  Regular alcohol consumption in males &gt;21 units per week (1 unit = ½ pint beer, 25 mL
             of 40% spirit or a 125 mL glass of wine)

          -  Current smokers and those who have smoked within the last 12 months; this includes
             cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide
             reading of greater than 10 ppm at screening or admission

          -  Radiation exposure, including that from the present study, excluding background
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study

          -  Subjects who have been enrolled in an ADME study in the last 12 months

          -  Subjects who do not have suitable veins for multiple venepunctures/cannulation as
             assessed by the investigator at screening

          -  Clinically significant abnormal biochemistry, haematology or urinalysis as judged by
             the investigator, including AST, ALT or alkaline phosphatase &gt;1.5 × upper limit of
             normal confirmed by repeat testing 18. Positive drugs of abuse test result

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          -  Evidence of renal impairment at screening, as indicated by an estimated creatinine
             clearance (CLcr) of &lt;90 mL/min using the Cockcroft-Gault equation

          -  History of clinically significant psychiatric, cardiovascular, renal, hepatic, chronic
             respiratory or gastrointestinal disease as judged by the investigator

          -  History of gastrointestinal surgery (except appendectomy) or any condition that may
             affect the absorption, distribution, metabolism or excretion of study drug in the
             opinion of the investigator

          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

          -  Presence or history of clinically significant allergy (including food or drug allergy)
             requiring treatment, as judged by the investigator. Hayfever is allowed unless it is
             active

          -  Donation or loss of greater than 400 mL of blood within the 3 months prior to IMP dose

          -  Subjects who have consumed St John's wort, red wine, Seville oranges, grapefruit or
             grapefruit juice within 7 days prior to dosing. Subjects must be willing to refrain
             from consuming such products until the last PK sample

          -  Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Clinical Ltd.</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

